| Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group … JP Donnelly, SC Chen, CA Kauffman, WJ Steinbach, JW Baddley, ... Clinical Infectious Diseases 71 (6), 1367-1376, 2020 | 1948 | 2020 |
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients OA Cornely, M Bassetti, T Calandra, J Garbino, BJ Kullberg, O Lortholary, ... Clinical Microbiology and Infection 18, 19-37, 2012 | 1308 | 2012 |
| Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae: Importance of Combination … M Tumbarello, P Viale, C Viscoli, EM Trecarichi, F Tumietto, A Marchese, ... Clinical infectious diseases 55 (7), 943-950, 2012 | 1139 | 2012 |
| DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? JA Roberts, SK Paul, M Akova, M Bassetti, JJ De Waele, G Dimopoulos, ... Clinical infectious diseases 58 (8), 1072-1083, 2014 | 1067 | 2014 |
| How to manage Pseudomonas aeruginosa infections M Bassetti, A Vena, A Croxatto, E Righi, B Guery Drugs in context 7, 2018 | 846 | 2018 |
| Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance P Koehler, M Bassetti, A Chakrabarti, SCA Chen, AL Colombo, M Hoenigl, ... The Lancet Infectious Diseases 21 (6), e149-e162, 2021 | 761 | 2021 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 739 | 2021 |
| Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual … SG Muthuri, S Venkatesan, PR Myles, J Leonardi-Bee, TSA Al Khuwaitir, ... The lancet Respiratory medicine 2 (5), 395-404, 2014 | 735 | 2014 |
| Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a … PNA Harris, PA Tambyah, DC Lye, Y Mo, TH Lee, M Yilmaz, TH Alenazi, ... Jama 320 (10), 984-994, 2018 | 640 | 2018 |
| Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# MH Abdul-Aziz, JWC Alffenaar, M Bassetti, H Bracht, G Dimopoulos, ... Intensive care medicine 46, 1127-1153, 2020 | 609 | 2020 |
| Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study M Tumbarello, EM Trecarichi, FG De Rosa, M Giannella, DR Giacobbe, ... Journal of Antimicrobial Chemotherapy 70 (7), 2133-2143, 2015 | 577 | 2015 |
| New antibiotics for bad bugs: where are we? M Bassetti, M Merelli, C Temperoni, A Astilean Annals of clinical microbiology and antimicrobials 12, 1-15, 2013 | 571 | 2013 |
| The novel Chinese coronavirus (2019‐nCoV) infections: Challenges for fighting the storm M Bassetti, A Vena, DR Giacobbe European journal of clinical investigation 50 (3), e13209, 2020 | 570 | 2020 |
| Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a … M Bassetti, R Echols, Y Matsunaga, M Ariyasu, Y Doi, R Ferrer, TP Lodise, ... The Lancet infectious diseases 21 (2), 226-240, 2021 | 539 | 2021 |
| Epidemiological trends in nosocomial candidemia in intensive care M Bassetti, E Righi, A Costa, R Fasce, MP Molinari, R Rosso, ... BMC Infectious Diseases 6, 1-6, 2006 | 477 | 2006 |
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures M Cuenca‐Estrella, PE Verweij, MC Arendrup, S Arikan‐Akdagli, J Bille, ... Clinical Microbiology and Infection 18, 9-18, 2012 | 470 | 2012 |
| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature medicine 27 (10), 1752-1760, 2021 | 458 | 2021 |
| European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli … M Paul, E Carrara, P Retamar, T Tängdén, R Bitterman, RA Bonomo, ... Clinical Microbiology and Infection 28 (4), 521-547, 2022 | 446 | 2022 |
| Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A … E Durante-Mangoni, G Signoriello, R Andini, A Mattei, M De Cristoforo, ... Clinical infectious diseases 57 (3), 349-358, 2013 | 438 | 2013 |
| Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial RG Wunderink, EJ Giamarellos-Bourboulis, G Rahav, AJ Mathers, ... Infectious diseases and therapy 7 (4), 439-455, 2018 | 388 | 2018 |
